Zobrazeno 1 - 10
of 50
pro vyhledávání: '"S. Wolowacz"'
Autor:
M.J. Hochmair, E. Nadal, Y. D’yachkova, T. Puri, A. Vickers, S. Wolowacz, X. Wang, U. Kiiskinen
Publikováno v:
Journal of Thoracic Oncology. 18:S62-S63
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f0b2770b0a6e71ee81aa49dba972741
https://doi.org/10.1016/s1556-0864(23)00292-7
https://doi.org/10.1016/s1556-0864(23)00292-7
Publikováno v:
European Heart Journal. 43
Background Lowering LDL-C treatment goals in the 2019 ESC/EAS guidelines necessitates greater use of combination therapies (1). Cost of PCSK9 inhibitors (PCSK9i) and efficacy of ezetimibe alone as add on therapies limit population level achievement o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ffd1bc669b26eb94d11162ce441d07a
https://doi.org/10.1093/eurheartj/ehac544.2377
https://doi.org/10.1093/eurheartj/ehac544.2377
Publikováno v:
Value in Health. 25:S395
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4853a371f55159ca3e5d5432d0c7638e
https://doi.org/10.1016/j.jval.2022.09.1964
https://doi.org/10.1016/j.jval.2022.09.1964
Publikováno v:
Value in Health. 25:S542
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::524d0282c4509667f1f726f7e27429b8
https://doi.org/10.1016/j.jval.2022.04.1358
https://doi.org/10.1016/j.jval.2022.04.1358
Publikováno v:
Value in Health. 25:S200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83584c5c98d93d2e35b244c12c8b657a
https://doi.org/10.1016/j.jval.2021.11.970
https://doi.org/10.1016/j.jval.2021.11.970
Publikováno v:
Value in Health. 25:S101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8be86f5ce08bde10a7dc920122a0474
https://doi.org/10.1016/j.jval.2021.11.480
https://doi.org/10.1016/j.jval.2021.11.480
Publikováno v:
Value in Health. 22:S330
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c8441d585855cf71d255f361d878475
https://doi.org/10.1016/j.jval.2019.04.1613
https://doi.org/10.1016/j.jval.2019.04.1613
Autor:
Richard Norman, Ron Goeree, Philip Clarke, Lynda C. Doward, S. Wolowacz, Andrew Lloyd, Vasily Belozeroff, Andrew Briggs
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 19(6)
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c16af656e5015187b19872d6b5539dc8
https://pubmed.ncbi.nlm.nih.gov/27712695
https://pubmed.ncbi.nlm.nih.gov/27712695
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Gundgaard, S. Wolowacz, Barrie Chubb, Melanie J. Davies, Andrew Briggs, P Shannon, I Pearson
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association. 32(8)
Aims To develop a health economic model to evaluate the cost-effectiveness of new interventions for Type 1 diabetes mellitus by their effects on long-term complications (measured through mean HbA1c) while capturing the impact of treatment on hypoglyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3989b8eba7e9ac86d44af8658d172ab2
https://pubmed.ncbi.nlm.nih.gov/25484028
https://pubmed.ncbi.nlm.nih.gov/25484028